BioSpace News Archive

Compact, battery-operated analytical device delivers precision and portability to transform on-site diagnostics and screening across medical, food and industrial applications.

Ohana Biosciences, a clinical-stage biotechnology company pioneering reproductive medicine through an industry-first platform of sperm-based technologies, today announced that Amber Salzman, Ph.D., President and Chief Executive Officer of Ohana, will present a company overview at the 40th Annual Cowen Health Care Conference on Monday, March 2, 2020 at 9:30 a.m. E.T. in Boston, MA.

Feb. 24, 2020 13:00 UTC Takeda Announces U.S. FDA Grants Priority Review for Supplemental New Drug Application for ALUNBRIG ® (brigatinib) as a First-Line Treatment for ALK+ Metastatic Non-Small Cell Lung Cancer – ALUNBRIG has Potential to Expand its Indication in ALK+ Metastatic Non-Small Cell Lung Cancer – – Prescription Drug User Fee Act (PDUFA) Target Action Date Set for June 23, 2020 – CAMBRIDGE, Mass. & OSAKA, Japan--( BUSINESS WIRE )-- Takeda Pharmaceu

ASLAN Pharmaceuticals Limited announced its presentation at the 9th Annual SVB Leerink Global Healthcare Conference.

Clover Biopharmaceuticals, a China based global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced that it has entered into a research collaboration with GSK for its protein-based coronavirus vaccine candidate.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that aggregated results from 309 children treated with Ryoncil™ (remestemcel-L) were presented at the American Society for Transplantation Cellular Therapy and the Center for International Blood & Bone Marrow Transplant Research (TCT) meeting in Orlando, Florida on February 22.

Aptorum Group Limited (“Aptorum Group”), a pharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the commercialization of its dietary supplement for women undergoing menopause and experiencing related symptoms

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the Cowen & Co. 40th Annual Health Care Conference

Avivagen Inc. (TSXV:VIV) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that enhance feed intake and safely support immune function, thereby supporting general health and performance, is pleased to announce positive and statistically significant results from its recently completed New Zealand dairy trial that demonstrated OxC-beta™ Livestock’s contribution against sub-clinical mastitis.

Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today provided business and pipeline updates and reported fourth quarter and full year 2019 financial results.